Yes,, the incredible, continuing survival of the patients - wuthout the need for assisted swallowing and respiration and is one reason why I'm bemused by people carrying over as if there is a risk that MPL will not find a medical use. Each new day that continues is a small miracle. It's stuff like this, along with all the wonderful biomarker results, the visible suppression of the MND inflammations, and the statements made by Professor Susan Maher way back in the first half of last year, that got me to switch over from my usual cautious statements up to the end of 2022, to increasing excitement about the MND trial, and of course why Buckland like boilerplate statements about clinical trial risk are a absolutely laughable, along with the backup that we know now from years of research and this last human trial that MPL has a future anyway as a safe and easy to use mTOR inhibitor for something or other anyway.
- Forums
- ASX - By Stock
- Ann: Extension Study Begins, Analysis Suggests Survival Benefit
Yes,, the incredible, continuing survival of the patients -...
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 51393 | 22.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.0¢ | 25000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 31393 | 0.225 |
1 | 232000 | 0.220 |
1 | 2325 | 0.215 |
7 | 47261 | 0.210 |
5 | 198228 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.210 | 25000 | 1 |
0.220 | 100000 | 1 |
0.230 | 43928 | 4 |
0.240 | 44200 | 1 |
0.245 | 55000 | 4 |
Last trade - 09.59am 07/05/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online